Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR, NMPA) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Neural Cardiac Therapy for Heart Failure Study (NECTAR-HF)

NCT: NCT01385176 · ACTIVE_NOT_RECRUITING

NCT IDNCT01385176
StatusACTIVE_NOT_RECRUITING
Start Date2011-09-21
Completion2026-06-30

Brief Summary

The NECTAR-HF feasibility trial is designed to evaluate the application of right vagal nerve stimulation in heart failure patients with a New York Heart Association Class III, an ejection fraction equal to or less than 35 %, and a narrow QRS duration equal to or less than 130 ms.

Frequently Asked Questions

What is Neural Cardiac Therapy for Heart Failure Study (NECTAR-HF)?

Neural Cardiac Therapy for Heart Failure Study (NECTAR-HF) is a clinical trial registered under NCT01385176. Current status: ACTIVE_NOT_RECRUITING.

What is the status of NCT01385176?

The current status of NCT01385176 (Neural Cardiac Therapy for Heart Failure Study (NECTAR-HF)) is: ACTIVE_NOT_RECRUITING.

When did Neural Cardiac Therapy for Heart Failure Study (NECTAR-HF) start?

Neural Cardiac Therapy for Heart Failure Study (NECTAR-HF) started on 2011-09-21.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.